Research brief · 2026-09-09
What Is a Systematic Review, and Why Does It Outrank a Single Study?
In 1999, the Lancet published the GISSI-Prevenzione trial: 11,324 people who had survived a recent heart attack, randomized to fish oil, vitamin E, both, or neither, and followed for three and a half years. Fish oil lowered the combined endpoint of death, heart attack or stroke by 10 to 15 percent depending on the analysis, and cardiovascular death by 30 percent in the four-way analysis. Vitamin E did nothing. One trial, published once, and it fed into cardiology guidelines and a consumer fish-oil market.
A systematic review is not a summary of what has been published. It follows a pre-registered protocol, searches multiple databases for every trial that asked the same question, applies the same inclusion criteria to all of them, formally assesses each trial's risk of bias, and, when the trials are similar enough, pools them into one estimate, weighting larger and more precise trials more heavily. A trial asks what happened in this group at this time. A review asks whether that holds up everywhere.
Twenty-one years later, the 2020 Cochrane review by Abdelhamid and colleagues pooled 86 randomized trials and 162,796 participants. All-cause mortality showed a relative risk of 0.97, precise enough to call no effect with confidence. Cardiovascular mortality came in at 0.92, an 8 percent reduction, real but far short of GISSI's 30 percent. The one outcome that stayed favorable, coronary heart disease death, translated to a number needed to treat of 334, and the review rated it low-certainty.
Pooling narrows the answer because any single trial is one draw of chance in one population, while many trials across countries and decades test whether an effect generalizes, and a good review hunts for null and unpublished studies. None of this makes single trials worthless. What the review cannot settle is whether GISSI's effect was real and shrank, or chance, or a product of how cardiac care changed. Decisions about supplements after a cardiac event belong with a physician. Sources are listed below.
Sources
- GISSI-Prevenzione Investigators, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction (n=11,324)
- Lancet, 1999
- Abdelhamid AS et al., Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (86 trials, n=162,796)
- Cochrane Database of Systematic Reviews, 2020
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.